Dear All: CDC have today released an update to their 2019 threat list (i.e., an update to CDC’s priority pathogen list or PPL). Here are the links you need: The webpage for the new report A PowerPoint (.pptx) summarizing all the PPLs to date The PowerPoint as a .pdf.. The AMR.Solutions webpage summarizing all the

Dear All: NIAID/DMID have released their 2027 Omnibus Broad Agency Announcement (BAA) entitled “Development of Medical Interventions for Infectious Diseases.” The key starting point is this link: https://sam.gov/workspace/contract/opp/5f75330f42ee4145990fe6a51a3dc84e/view. Much of this BAA is antiviral but Research Area 2.4 is on point for this newsletter’s audience. The call here is to “improve patient outcomes against serious

Dear All: Oh, no! Hot on the heels of the excellent talk at GAMRIC by Karen Bush in which the importance of relebactam as one of our most advanced beta-lactamase inhibitors was highlighted, we have this: Screenshot from drugs.com Yes, that’s right, Merck have notified the US FDA that imipenem-cilastatin-relebactam (RECARBIO) is being withdrawn from